middle.news
Mayne Pharma Reports 6% Revenue Decline Amid Women’s Health Growth and DistributeRx Expansion
9:29am on Friday 31st of July, 2026 AEST
•
Pharmaceuticals
Read Story
Mayne Pharma Reports 6% Revenue Decline Amid Women’s Health Growth and DistributeRx Expansion
9:29am on Friday 31st of July, 2026 AEST
Key Points
FY26 revenue down 6% to $383.7 million
Women’s Health portfolio prescriptions grow notably
DistributeRx expands capacity seven-fold with new facility
Underlying EBITDA declines 33% due to legal and investment costs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE